Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
A new weight loss pill outperformed Novo Nordisk's version
Pills are displayed with open pill bottles on top of a white counter top in the kitchen.Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill.
New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
A new weight loss drug could beat Ozempic's side effect problem
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.
Weight Loss Drugs May Be a New Alternative to Knee Replacements
A new study suggests that weekly self-injections of the weight loss drug semaglutide could reduce knee pain from moderate osteoarthritis by nearly 50%.
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported on Wednesday better-than-expected quarterly sales of its popular Wegovy weight-loss drug, reassuring investors worried the drugmaker was losing its lead in the fast-growing obesity drug market to U.
Obesity drug maker Novo Nordisk posts strong profit
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.
Novo Nordisk Posts Solid Earnings. Weight-Loss Drug Wegovy Sales Beat Estimates.
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. W
Novo Nordisk is aware of 10 deaths from compounded weight-loss drug copies
Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular weight-loss and diabetes drugs, the drugmaker's finance chief said on Wednesday.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
An injection pen of Zepbound, Eli Lilly’s weight-loss drug, is displayed in New York City, December 11, 2023.
Microdosing Ozempic? Why some people are playing doctor with weight-loss drugs
the Hollywood resident found herself mixing vials in her kitchen to create her own doses of a popular weight-loss drug.
Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections
Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections - As weight-loss injections emerge as key players in ...
The Jerusalem Post Blogs on MSN3d
Weight loss injections ease knee pain - study
The drug semaglutide, sold under the brand name Ozempic for diabetes management and Wegovy for weight loss, has now ...
News Medical on MSN2d
Weight loss drug semaglutide may offer relief for knee arthritis pain
Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.
Viking Therapeutics' New Weight Loss Pill Shows Promising Results
Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...